127 related articles for article (PubMed ID: 33689795)
1. Adding high-dose celecoxib to increase effectiveness of standard glioblastoma chemoirradiation.
Kast RE
Ann Pharm Fr; 2021 Sep; 79(5):481-488. PubMed ID: 33689795
[TBL] [Abstract][Full Text] [Related]
2. CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Kast RE; Karpel-Massler G; Halatsch ME
Oncotarget; 2014 Sep; 5(18):8052-82. PubMed ID: 25211298
[TBL] [Abstract][Full Text] [Related]
3. Adding perphenazine to increase effectiveness of standard glioblastoma chemoirradiation.
Kast RE
J BUON; 2020; 25(4):1676-1686. PubMed ID: 33099901
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy.
Skaga E; Skaga IØ; Grieg Z; Sandberg CJ; Langmoen IA; Vik-Mo EO
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1495-1507. PubMed ID: 31028540
[TBL] [Abstract][Full Text] [Related]
5. Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.
Stockhammer F; Misch M; Koch A; Czabanka M; Plotkin M; Blechschmidt C; Tuettenberg J; Vajkoczy P
J Neurooncol; 2010 Dec; 100(3):407-15. PubMed ID: 20446016
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of cyclooxygenase-2 correlates with resistance to radiation in human prostate adenocarcinoma cells.
Anai S; Tanaka M; Shiverick KT; Kim W; Takada S; Boehlein S; Goodison S; Mizokami A; Rosser CJ
J Urol; 2007 May; 177(5):1913-7. PubMed ID: 17437847
[TBL] [Abstract][Full Text] [Related]
8. Celecoxib substituted biotinylated poly(amidoamine) G3 dendrimer as potential treatment for temozolomide resistant glioma therapy and anti-nematode agent.
Uram Ł; Markowicz J; Misiorek M; Filipowicz-Rachwał A; Wołowiec S; Wałajtys-Rode E
Eur J Pharm Sci; 2020 Sep; 152():105439. PubMed ID: 32615261
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis.
Kang KB; Wang TT; Woon CT; Cheah ES; Moore XL; Zhu C; Wong MC
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):888-96. PubMed ID: 17293239
[TBL] [Abstract][Full Text] [Related]
10. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.
Gilbert MR; Gonzalez J; Hunter K; Hess K; Giglio P; Chang E; Puduvalli V; Groves MD; Colman H; Conrad C; Levin V; Woo S; Mahajan A; de Groot J; Yung WK
Neuro Oncol; 2010 Nov; 12(11):1167-72. PubMed ID: 20729242
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults.
Kesari S; Schiff D; Henson JW; Muzikansky A; Gigas DC; Doherty L; Batchelor TT; Longtine JA; Ligon KL; Weaver S; Laforme A; Ramakrishna N; Black PM; Drappatz J; Ciampa A; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2008 Jun; 10(3):300-8. PubMed ID: 18403492
[TBL] [Abstract][Full Text] [Related]
12. Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma.
Huang J; Campian JL; Gujar AD; Tsien C; Ansstas G; Tran DD; DeWees TA; Lockhart AC; Kim AH
J Neurooncol; 2018 May; 138(1):105-111. PubMed ID: 29374809
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Malmström A; Grønberg BH; Marosi C; Stupp R; Frappaz D; Schultz H; Abacioglu U; Tavelin B; Lhermitte B; Hegi ME; Rosell J; Henriksson R;
Lancet Oncol; 2012 Sep; 13(9):916-26. PubMed ID: 22877848
[TBL] [Abstract][Full Text] [Related]
14. Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
Bi N; Liang J; Zhou Z; Chen D; Fu Z; Yang X; Feng Q; Hui Z; Xiao Z; Lv J; Wang X; Zhang T; Wang X; Deng L; Wang W; Wang J; Liu L; Hu C; Wang L
JAMA Netw Open; 2019 Dec; 2(12):e1918070. PubMed ID: 31851351
[TBL] [Abstract][Full Text] [Related]
15. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Kast RE; Boockvar JA; Brüning A; Cappello F; Chang WW; Cvek B; Dou QP; Duenas-Gonzalez A; Efferth T; Focosi D; Ghaffari SH; Karpel-Massler G; Ketola K; Khoshnevisan A; Keizman D; Magné N; Marosi C; McDonald K; Muñoz M; Paranjpe A; Pourgholami MH; Sardi I; Sella A; Srivenugopal KS; Tuccori M; Wang W; Wirtz CR; Halatsch ME
Oncotarget; 2013 Apr; 4(4):502-30. PubMed ID: 23594434
[TBL] [Abstract][Full Text] [Related]
16. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
17. Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis.
Welzel G; Gehweiler J; Brehmer S; Appelt JU; von Deimling A; Seiz-Rosenhagen M; Schmiedek P; Wenz F; Giordano FA
J Neurooncol; 2015 Sep; 124(2):265-73. PubMed ID: 26045360
[TBL] [Abstract][Full Text] [Related]
18. COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Majchrzak-Celińska A; Misiorek JO; Kruhlenia N; Przybyl L; Kleszcz R; Rolle K; Krajka-Kuźniak V
BMC Cancer; 2021 May; 21(1):493. PubMed ID: 33941107
[TBL] [Abstract][Full Text] [Related]
19. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Walbert T; Gilbert MR; Groves MD; Puduvalli VK; Yung WK; Conrad CA; Bobustuc GC; Colman H; Hsu SH; Bekele BN; Qiao W; Levin VA
J Neurooncol; 2011 Apr; 102(2):273-80. PubMed ID: 20652724
[TBL] [Abstract][Full Text] [Related]
20. The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II.
Knudsen JF; Carlsson U; Hammarström P; Sokol GH; Cantilena LR
Inflammation; 2004 Oct; 28(5):285-90. PubMed ID: 16134002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
